A review of anti-D treatment of childhood idiopathic thrombocytopenic purpura

Treatment of childhood idiopathic thrombocytopenic purpura is still an area of controversy. We reviewed the literature on anti-D treatment. Most studies used intravenous anti-D. Single doses of 50 mu g/kg increased the platelet count to >= 20 x 10(9)/L in 70% of the children within 3 days. intravenous anti-D seems safe in classic childhood ITP although hemolysis and occasionally renal failure may be of concern. A few studies reported intramuscularly or subcutaneously administered anti-D. Further studies on the optimal dose and route of administration of anti-D are warranted. Pediatr Blood Cancer 2006;47:717-720. (c) 2006 Wiley-Liss, Inc.